Physician profile
Gregory S Pepper
NPI 1386674901
$22,237.08
in general payments reported to CMS, 2019-2025
40 companies · $4,957 in 2025
The $4,957 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $905 · 2020: $2,844 · 2021: $1,465 · 2022: $3,527 · 2023: $1,869 · 2024: $6,669 · 2025: $4,957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,204 · Travel and Lodging: $6,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,204.42 |
| Travel and Lodging | $6,291.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $10,608.28 | 2021-2025 | Micra, Mycarelink, Cobalt Dr Mri Surescan |
| Boston Scientific Corporation | $3,122.33 | 2019-2025 | Farapulse, Bodyguardian, Lux-Dx Insertable Cardiac Monitor |
| Medtronic Vascular, INC. | $2,414.42 | 2019-2020 | |
| Biosense Webster, INC. | $1,147.93 | 2023-2025 | Carto 3, Pentaray Nav, Soundstar |
| E.R. Squibb & Sons, L.L.C. | $786.16 | 2019-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $641.97 | 2019-2025 | Aveir, Cardiomems, Ensite Precision |
| Irhythm Technologies, INC. | $339.24 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Janssen Pharmaceuticals, INC | $310.80 | 2019-2024 | Xarelto |
| Pfizer INC. | $261.78 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $259.71 | 2019-2023 | Lifevest |
| Astellas Pharma US INC | $258.10 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $245.66 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $236.67 | 2019-2023 | |
| Cardiva Medical, INC. | $198.05 | 2022-2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Amgen INC. | $175.17 | 2021-2025 | Repatha |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Pepper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.